Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus

EMBO Molecular Medicine

Volumn 2, Issue 7, 2010, Pages 275-288

  Roos, Frederik C ^a,b   Roberts, Andrew M ^a   Hwang, Irene I L ^a   Moriyama, Eduardo H ^c   Evans, Andrew J ^a,c   Sybingco, Stephanie ^a   Watson, Ian R ^a,d   Carneiro, Leticia A M ^a   Gedye, Craig ^c   Girardin, Stephen E ^a   Ailles, Laurie E ^c   Jewett, Michael A S ^c   Milosevic, Michael ^c   Wilson, Brian C ^c   Bell, John C ^e   Der, Sandy D ^a   Ohh, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

EMCV; HIF; NF kB; RCC; VHL

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYPOXIA INDUCIBLE FACTOR; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 2; INTERLEUKIN 6; INTERLEUKIN 8; ONCOLYTIC VIRUS; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; SMALL INTERFERING RNA; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; ENCEPHALOMYOCARDITIS VIRUS; GENE EXPRESSION PROFILING; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; APOPTOSIS; CARCINOMA, RENAL CELL; GENETICS; KIDNEY NEOPLASMS; METABOLISM; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; ENCEPHALOMYOCARDITIS VIRUS; KIDNEY NEOPLASMS; MICE; MICE, SCID; NF-KAPPA B; ONCOLYTIC VIRUSES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 77956929126     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201000081     Document Type: Article

References (53)

1. Aghi M, Martuza RL (2005) Oncolytic viral therapies\the clinical experience. Oncogene 24: 7802-7816
2. Algire GH, Legallais FY (1949) Recent developments in the transparent-chamber technique as adapted to the mouse. J Natl Cancer Inst 10:225-253, incl 228 pl
3. An J, Rettig MB (2005) Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol 25: 7546-7556
4. Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Ann Rev Immunol 12: 141-179
5. Beg AA, Baltimore D (1996) An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274: 782-784
6. Bertin J, Armstrong RC, Ottilie S, Martin DA, Wang Y, Banks S, Wang GH, Senkevich TG, Alnemri ES, Moss B et al (1997) Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas-and TNFR1-induced apoptosis. Proc Natl Acad Sci USA 94: 1172-1176
7. Boulakia CA, Chen G, Ng FW, Teodoro JG, Branton PE, Nicholson DW, Poirier GG, Shore GC (1996) Bcl-2 and adenovirus E1B 19 kDA protein prevent E1A-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase. Oncogene 12: 529-535
8. Brewer LA, Lwamba HC, Murtaugh MP, Palmenberg AC, Brown C, Njenga MK (2001) Porcine encephalomyocarditis virus persists in pig myocardium and infects human myocardial cells. J Virol 75: 11621-11629
9. Brooks MA, Ali AN, Turner PC, Moyer RW (1995) A rabbitpox virus serpin gene controls host range by inhibiting apoptosis in restrictive cells. J Virol 69: 7688-7698
10. Bump NJ, Hackett M, Hugunin M, Seshagiri S, Brady K, Chen P, Ferenz C, Franklin S, Ghayur T, Li P et al (1995) Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science 269: 1885-1888
11. Chiocca EA (2002) Oncolytic viruses. Nat Rev 2: 938-950
12. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353: 2477-2490
13. Demers GW, Johnson DE, Tsai V, Wen SF, Quijano E, Machemer T, Philopena J, Ramachandra M, Howe JA, Shabram P et al (2003) Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy. Cancer Res 63: 4003-4008
14. Evans AJ, Russell RC, Roche O, Burry TN, Fish JE, Chow VW, Kim WY, Saravanan A, Maynard MA, Gervais ML et al (2007) VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 27: 157-169
15. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18: 2195-2224
16. Hershberger PA, Dickson JA, FriesenPD (1992) Site-specific mutagenesis of the 35-kilodalton protein gene encoded by Autographa californica nuclear polyhedrosis virus: cell line-specific effects on virus replication. J Virol 66: 5525-5533
17. Hwang II, Watson IR, Der SD, Ohh M (2006) Loss of VHL confers HIF-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response. J Virol 80: 10712-10723.
18. Kaelin WG Jr, (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev 2: 673-682
19. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev 2: 301-310
20. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG (2005) Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neurooncology 7: 134-153
21. Kim YK, Jang SK (2002) Continuous heat shock enhances translational initiation directed by internal ribosomal entry site. Biochem Biophys Res Commun 297: 224-231
22. Kim S, La Motte-Mohs RN, Rudolph D, Zuniga-Pflucker JC, Mak TW (2003) The role of nuclear factor-kappaB essential modulator (NEMO) in B cell development and survival. Proc Natl Acad Sci USA 100: 1203-1208
23. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J et al (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6: 33-43
24. Laguna MP, Kummerlin I, Rioja J, de la Rosette JJ (2009) Biopsy of a renal mass: where are we now? Curr Opin Urol 19: 447-453
25. Laurie SA, Bell JC, Atkins HL, Roach J, Bamat MK, O'Neil JD, Roberts MS, Groene WS, Lorence RM (2006) A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res 12: 2555-2562
26. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275
27. Miao Y, Ni Y, Bosmans H, Yu J, Vaninbroukx J, Dymarkowski S, Zhang H, Marchal G (2001) Radiofrequency ablation for eradication of renal tumor in a rabbit model by using a cooled-tip electrode technique. Ann Surg Oncol 8: 651-657
28. Moran JM, Moxley MA, Buller RM, Corbett JA (2005) Encephalomyocarditis virus induces PKR-independent mitogen-activated protein kinase activation in macrophages. J Virol 79: 10226-10236
29. Nevins TA, Harder ZM, Korneluk RG, Holcik M (2003) Distinct regulation of internal ribosome entry site-mediated translation following cellular stress is mediated by apoptotic fragments of eIF4G translation initiation factor family members eIF4GI and p97/DAP5/NAT1. J Biol Chem 278: 3572-3579
30. Ngoi SM, Chien AC, Lee CG (2004) Exploiting internal ribosome entry sites in gene therapy vector design. Curr Gene Ther 4: 15-31
31. Norman KL, LeePW (2005) Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today 10: 847-855
32. O'Shea CC (2005) Viruses: tools for tumor target discovery, and agents for oncolytic therapies\an introduction. Oncogene 24: 7636-7639
33. Park JG, Ku JL, Park SY (2004) Isolation and culture of renal cancer cell lines. Methods Mol Med 88: 111-119
34. Pilder S, Logan J, Shenk T (1984) Deletion of the gene encoding the adenovirus 5 early region 1b 21,000-molecular-weight polypeptide leads to degradation of viral and host cell DNA. J Virol 52: 664-671
35. Qi H, Ohh M (2003) The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway. Cancer Res 63: 7076-7080
36. Ray CA, Black RA, Kronheim SR, Greenstreet TA, Sleath PR, Salvesen GS, Pickup DJ (1992) Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell 69: 597-604
37. Roberts AM, Ohh M (2008) Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau. Curr Opin Oncol 20: 83-89
38. Schepens B, Tinton SA, Bruynooghe Y, Beyaert R, Cornelis S (2005) The polypyrimidine tract-binding protein stimulates HIF-1alpha IRES-mediated translation during hypoxia. Nucleic Acids Res 33: 6884-6894
39. Schwarz EM, Badorff C, Hiura TS, Wessely R, Badorff A, Verma IM, Knowlton KU (1998) NF-kappaB-mediated inhibition of apoptosis is required for encephalomyocarditis virus virulence: a mechanism of resistance in p50 knockout mice. J Virol 72: 5654-5660
40. Sellin CI, Horvat B (2009) Current animal models: transgenic animal models for the study of measles pathogenesis. Curr Top Microbiol Immunol 330: 111-127
41. Sha WC, Liou HC, Tuomanen EI, Baltimore D (1995) Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 80: 321-330
42. Shen Y, Shenk TE (1995) Viruses and apoptosis. Curr Opin Genet Dev 5: 105-111
43. Shin HM, Kim MH, Kim BH, Jung SH, Kim YS, Park HJ, Hong JT, Min KR, Kim Y, (2004) Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. FEBS Lett 571: 50-54
44. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H et al (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer cell 4: 263-275
45. Sufan RI, Moriyama EH, Mariampillai A, Roche O, Evans AJ, Alajez NM, Vitkin IA, Yang VX, Liu FF, Wilson BC et al (2009) Oxygen-independent degradation of HIF-alpha via bioengineered VHL tumour suppressor complex. EMBO Mol Med 1: 66-78
46. Teodoro JG, Branton PE (1997) Regulation of apoptosis by viral gene products. J Virol 71: 1739-1746
47. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M et al (1997) Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386: 517-521
48. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM (1996) Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274: 787-789
49. Wakimoto H, Fulci G, Tyminski E, Chiocca EA (2004) Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther 11: 214-223
50. Wang CY, Mayo MW, Baldwin AS Jr, (1996) TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787
51. Watson IR, Blanch A, Lin DC, Ohh M, Irwin MS (2006) Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J Biol Chem 281: 34096-34103
52. Williamson JD, Reith RW, Jeffrey LJ, Arrand JR, Mackett M (1990) Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol 71: 2761-2767
53. Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X, Zhang L, Kim WY, Olumi AF, Kaelin WG Jr, (2007) pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 28: 15-27